Renal Cell Carcinoma – MMab

For In Vitro Diagnostic Use

Renal Cell Carcinoma, also known as a Gurnistical Tumor, is the most common form of kidney cancer arising from the renal tubule. It is also the most common type of kidney cancer in adults. Initial treatment is surgery because it is notoriously resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy. Renal Cell Carcinoma antibody recognizes a 200 kDa glycoprotein localized in the brush border of the proximal renal tubule. This antibody immunoreacts with approximately 90% of Primary Renal Cell Carcinomas and approximately 85% of Metastatic Renal Cell Carcinomas. Other tumors that may react with this antibody are Parathyroid Adenoma, an occasional Breast Carcinoma. Nephroblastoma, Oncocytoma, Mesoblastic Nephroma, Transitional Cell Carcinoma, and Angiomyolipoma are not labeled with this antibody.

Antibody Type: Mouse Monoclonal
Clone: PN-15
Isotype: IgG1/K
Reactivity: Paraffin, Frozen
Localization: Cytoplasmic, Membranous
Control: Kidney, Breast, Thyroid, Renal Cell Carcinoma

Anti-Renal Cell Carcinoma is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.